📌 Key Takeaways
China has revised its 2026 review guidelines for aesthetic hyaluronic acid fillers
Requirements for clinical data, safety evidence, and product characteristics have been strengthened
Scientific evaluation standards for filler products within the medical device regulatory framework have been further clarified
In February 2026, the Center for Medical Device Evaluation (CMDE) under China’s National Medical Products Administration (NMPA) released an updated regulatory document titled:
“Guidelines for the Registration and Review of Injectable Sodium Hyaluronate Products for Aesthetic Use (2026 Revision).”
The guideline applies to aesthetic hyaluronic acid fillers used for indications such as:
correction of nasolabial folds
wrinkle improvement
facial volume augmentation
The revised guideline took effect immediately upon publication.
The update introduces a clearer regulatory structure requiring manufacturers to submit:
scientific evidence supporting product characteristics
clinical performance evaluation
in-vivo degradation data
As a result, the scientific review framework for aesthetic filler products within the medical device regulatory system has been further clarified.
INDEX
What Has Changed in China’s Filler Review Process
One of the key features of the updated guideline is the introduction of a “research item matrix.”
The guideline outlines more than 30 performance evaluation parameters.
In principle, manufacturers are expected to submit research data corresponding to these parameters.
If a company considers a parameter “not applicable,”
a scientific justification must be provided.
This approach is intended to strengthen:
regulatory transparency
scientific evidence supporting product safety and performance
How Strict Is the New Evaluation Framework?
The revised guideline clarifies requirements across several areas.
■ Raw Material Characterization
For pre-crosslinked hyaluronic acid materials, manufacturers must provide data such as:
-
molecular weight
-
molecular weight distribution
■ Degradation and Metabolism Studies
Products must include data describing in vivo degradation behavior to demonstrate how the material behaves in the body.
■ Scientific Basis for Dosage
Manufacturers must provide clinical or preclinical evidence supporting:
maximum single injection dose
maximum total dose per treatment
recommended reinjection intervals
■ Biological Safety Evaluation
In addition to conventional biocompatibility testing, expanded risk assessment now includes:
-
particle-related safety considerations
-
maximum dose simulation analysis
Why This Matters for the Aesthetic Medicine Industry
China is currently one of the largest aesthetic medicine markets in the world, and its hyaluronic acid filler sector has expanded rapidly in recent years.
With the revised guideline, regulatory expectations related to:
clinical trial design
product data management
regulatory submission strategy
may become more important from the early stages of product development.
For international manufacturers, the updated framework may also influence market entry strategies for China.
Editor’s Point | The Growing Scientificization of Aesthetic Products
Hyaluronic acid fillers have become widely used in aesthetic medicine.
At the same time, regulators in many regions are gradually strengthening scientific review requirements for products used in aesthetic procedures.
The revised Chinese guideline emphasizes clearer expectations regarding:
-
raw material characterization
-
clinical data
-
safety evaluation
As the aesthetic medicine market continues to expand, regulatory review frameworks are increasingly shifting toward evidence-based product evaluation.
Summary
-
China has revised the regulatory guideline for aesthetic hyaluronic acid fillers
-
Clinical performance, product characteristics, and safety data requirements have been clarified
-
More than 30 evaluation parameters are outlined
-
The scientific review framework for filler products within medical device regulation has been strengthened
Source
Center for Medical Device Evaluation (CMDE), National Medical Products Administration (NMPA), China
Announcement on the Release of the “Guidelines for Registration and Review of Injectable Sodium Hyaluronate Products for Aesthetic Use (2026 Revision)”
NERO’s Mission
NERO reports on global developments in aesthetic medicine
through the lens of structure, ethics, and long-term consequence.
Rather than amplifying surface-level trends,
we examine how medical practices are regulated, commercialised, and normalised —
and what is reshaped when innovation moves faster than existing frameworks.
As aesthetic medicine expands beyond traditional clinical boundaries,
NERO focuses on the grey zones where definitions blur, responsibilities shift,
and medical decision-making becomes increasingly complex.
In an era of accelerating innovation,
NERO remains committed to transparency, critical scrutiny,
and responsible reporting —
so readers can understand not only what is new,
but what deserves closer examination before it becomes standard practice.
